Figure 1.

IFN‐γ ELISPOT. (A) Antigen‐specific T‐cell response. IFN‐γ ELISPOT was performed with splenocytes from untreated and ONCOS‐102‐treated mice to determine the specificity of tumor‐related T‐cells for the antigen mesothelin tumor treated with ONCOS‐102. (B) Mesothelioma murine cell line AB12 was implanted intraperitoneally (5 × 10⁵ cells/200 µL) in BALB/c mice (2 groups: 1 treated with ONCOS‐102 and the other with PBS; n = 6 mice). Repeated intraperitoneal injections of 1 × 10¹¹ ONCOS‐102 particles/200 µL were given on days 0, 3, and 6 after tumor formation. Tumor size was measured with a caliper on 2 dimensions on day 20. The longest and shortest diameter were recorded, and the tumor volume was calculated using a formula of 0.52 × length × (width)². (C) Left panels for the tumor treated with ONCOS‐102 and (D) PBS, respectively, stimulated with hexon pool, E1A pool (haplotype b), mesothelin pool, PMA, and Ionomycin, respectively (positive control). Error bars, mean ± SD: *p < .05, **p < .01, ***p < .001. BALB/c, bagg albino; ELISPOT, enzyme‐linked immunospot; IFN, interferon; PBS, phosphate‐buffered saline; PMA, phorbol 12‐myristate 13‐acetate; SD, standard deviation